Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2006

Laureate Pharma Will Continue to Manufacture Cytogen’s ProstaScint

  • Laureate Pharma renewed its agreement with Cytogen for the cGMP manufacture of ProstaScint®, Cytogen's Mab immunoconjugate that is used for imaging in patients diagnosed with prostate cancer.

    Under the agreement, Laureate will provide cGMP protein production and purification, conjugation of Cytogen's linker chelator, and aseptic filling services to support Cytogen's commercial ProstaScint requirements.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »